EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

EpiVax-Expansion

More Like This

PR Newswire associated0

EpiVax Drives Immunogenicity Innovation in 2024: Year in Review

PR Newswire associated0

Novel Immunogenicity Risk Assessment Platform, ISPRI, Facilitates Biologic Therapeutics Development

PR Newswire associated0

EpiVax Strengthens Technology Leadership Amid Immunoinformatics Advancements

PR Newswire associated0

EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO

Immunovia's new lab staffed and operational after rapid implementation

Intravacc Highlights Integrated Analytical Capabilities to Accelerate Vaccine and Biologics Development

PR Newswire associated0

EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs

PR Newswire associated0

EpiVax and FDA Scientists Publish New Insights on Immunogenicity Risks of Peptide-Related Impurities in Generic Teriparatide